JOURNAL OF RESEARCH IN PHARMACY, vol.26, no.4, pp.722-733, 2022 (ESCI)
Alcohol addiction is one of the leading causes which is associated with morbidity and mortality with outcomes in high healthcare and economic costs. Myricetin is a flavonoid that demonstrates therapeutic actions in many central nervous system diseases. In the current study, the conditioned place preference (CPP) tests were performed W examine the effects of myricetin on ethanol reward. During conditioning, intraperitoneal (i.p) administration of ethanol (2 g/kg) and serum physiologic were given on alternate days for 8 days. In order to evaluate the effect of myricetin on the development of alcohol addiction, myricetin was injected into mice 30 minutes before ethanol administration. Subsequently, a daily myricetin injection was performed to evaluate the effect of myricetin on the extinction of alcohol addiction. Finally, ethanol was administered 900 seconds after different dose myricetin administration, and reinstatement was evaluated immediately thereafter. Systemic ethanol (2 g/kg, i.p) administration significantly produced CPP. Myricetin (5 and 10 mg/kg, i.p) attenuated the development of ethanol addiction (p < 0.05). Systemic myricetin injections immediately after each extinction period precipitated extinction and decreased reinstatement (10 mg/kg, i.p, p < 0.05, respectively). Ethanol alone and in combination with myricetin did not change locomotor activity and motor coordination. As a result, it can be suggested that myricetin is effective in attenuating the rewarding effect of alcohol in mice and can be used for the adjunctive therapy for alcohol addiction. In addition, it will be appropriate to conduct mechanistic experimental studies regarding these results in the future.